#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The development of flow processes has gained tremendous interest in recent years in organic chemistry due to numerous advantages of such types of processes over classic batch approaches .
2-1	16-19	The	abstract[2]	new[2]	coref	3-27[19_2]
2-2	20-31	development	abstract[2]	new[2]	_	_
2-3	32-34	of	abstract[2]	new[2]	_	_
2-4	35-39	flow	abstract[2]|abstract|abstract[4]	new[2]|new|new[4]	coref|coref	2-24[0_4]|3-30
2-5	40-49	processes	abstract[2]|abstract[4]	new[2]|new[4]	_	_
2-6	50-53	has	_	_	_	_
2-7	54-60	gained	_	_	_	_
2-8	61-71	tremendous	organization[5]	new[5]	coref	6-5[46_5]
2-9	72-80	interest	organization[5]	new[5]	_	_
2-10	81-83	in	organization[5]	new[5]	_	_
2-11	84-90	recent	organization[5]|time[6]	new[5]|new[6]	_	_
2-12	91-96	years	organization[5]|time[6]	new[5]|new[6]	_	_
2-13	97-99	in	organization[5]|time[6]	new[5]|new[6]	_	_
2-14	100-107	organic	organization[5]|time[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
2-15	108-117	chemistry	organization[5]|time[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
2-16	118-121	due	_	_	_	_
2-17	122-124	to	_	_	_	_
2-18	125-133	numerous	abstract[8]	new[8]	coref	3-7[15_8]
2-19	134-144	advantages	abstract[8]	new[8]	_	_
2-20	145-147	of	abstract[8]	new[8]	_	_
2-21	148-152	such	abstract[8]|place[9]	new[8]|new[9]	_	_
2-22	153-158	types	abstract[8]|place[9]	new[8]|new[9]	_	_
2-23	159-161	of	abstract[8]|place[9]	new[8]|new[9]	_	_
2-24	162-171	processes	abstract[8]|place[9]|abstract	new[8]|new[9]|giv	coref	3-30[21_0]
2-25	172-176	over	abstract[8]|place[9]	new[8]|new[9]	_	_
2-26	177-184	classic	abstract[8]|place[9]|abstract[12]	new[8]|new[9]|new[12]	_	_
2-27	185-190	batch	abstract[8]|place[9]|quantity|abstract[12]	new[8]|new[9]|new|new[12]	coref	6-40
2-28	191-201	approaches	abstract[8]|place[9]|abstract[12]	new[8]|new[9]|new[12]	_	_
2-29	202-203	.	_	_	_	_

#Text=In addition to higher efficiency and safety advantages , the ability to ensure constant product quality has turned out to be a major driving force for the development of flow processes .
3-1	204-206	In	_	_	_	_
3-2	207-215	addition	_	_	_	_
3-3	216-218	to	_	_	_	_
3-4	219-225	higher	abstract[13]	new[13]	_	_
3-5	226-236	efficiency	abstract[13]	new[13]	_	_
3-6	237-240	and	_	_	_	_
3-7	241-247	safety	abstract|abstract[15]	new|giv[15]	_	_
3-8	248-258	advantages	abstract[15]	giv[15]	_	_
3-9	259-260	,	_	_	_	_
3-10	261-264	the	abstract[16]	new[16]	_	_
3-11	265-272	ability	abstract[16]	new[16]	_	_
3-12	273-275	to	_	_	_	_
3-13	276-282	ensure	_	_	_	_
3-14	283-291	constant	abstract[17]	new[17]	_	_
3-15	292-299	product	abstract[17]	new[17]	_	_
3-16	300-307	quality	abstract[17]	new[17]	_	_
3-17	308-311	has	_	_	_	_
3-18	312-318	turned	_	_	_	_
3-19	319-322	out	_	_	_	_
3-20	323-325	to	_	_	_	_
3-21	326-328	be	_	_	_	_
3-22	329-330	a	abstract[18]	new[18]	_	_
3-23	331-336	major	abstract[18]	new[18]	_	_
3-24	337-344	driving	abstract[18]	new[18]	_	_
3-25	345-350	force	abstract[18]	new[18]	_	_
3-26	351-354	for	abstract[18]	new[18]	_	_
3-27	355-358	the	abstract[18]|abstract[19]	new[18]|giv[19]	_	_
3-28	359-370	development	abstract[18]|abstract[19]	new[18]|giv[19]	_	_
3-29	371-373	of	abstract[18]|abstract[19]	new[18]|giv[19]	_	_
3-30	374-378	flow	abstract[18]|abstract[19]|abstract|abstract[21]	new[18]|giv[19]|giv|giv[21]	coref|coref	4-56|4-56[36_21]
3-31	379-388	processes	abstract[18]|abstract[19]|abstract[21]	new[18]|giv[19]|giv[21]	_	_
3-32	389-390	.	_	_	_	_

#Text=In particular , for active pharmaceutical ingredients ( APIs ) , this aspect is important , as the FDA along with the EPA , as the respective institutions in United States and Europe for approval of medicines , added aspects of continuous manufacturing to their guidelines , whereas for a long time the focus of flow processes was on “ classic ” chemical processes with , for example , hazardous and thermally labile substances and chemocatalytic reactions .
4-1	391-393	In	_	_	_	_
4-2	394-404	particular	_	_	_	_
4-3	405-406	,	_	_	_	_
4-4	407-410	for	_	_	_	_
4-5	411-417	active	abstract[22]	new[22]	appos	4-9[0_22]
4-6	418-432	pharmaceutical	abstract[22]	new[22]	_	_
4-7	433-444	ingredients	abstract[22]	new[22]	_	_
4-8	445-446	(	_	_	_	_
4-9	447-451	APIs	abstract	giv	_	_
4-10	452-453	)	_	_	_	_
4-11	454-455	,	_	_	_	_
4-12	456-460	this	abstract[24]	new[24]	_	_
4-13	461-467	aspect	abstract[24]	new[24]	_	_
4-14	468-470	is	_	_	_	_
4-15	471-480	important	_	_	_	_
4-16	481-482	,	_	_	_	_
4-17	483-485	as	_	_	_	_
4-18	486-489	the	_	_	_	_
4-19	490-493	FDA	_	_	_	_
4-20	494-499	along	_	_	_	_
4-21	500-504	with	_	_	_	_
4-22	505-508	the	organization[25]	new[25]	_	_
4-23	509-512	EPA	organization[25]	new[25]	_	_
4-24	513-514	,	_	_	_	_
4-25	515-517	as	_	_	_	_
4-26	518-521	the	_	_	_	_
4-27	522-532	respective	_	_	_	_
4-28	533-545	institutions	_	_	_	_
4-29	546-548	in	_	_	_	_
4-30	549-555	United	place[26]	new[26]	_	_
4-31	556-562	States	place[26]	new[26]	_	_
4-32	563-566	and	_	_	_	_
4-33	567-573	Europe	place	new	_	_
4-34	574-577	for	_	_	_	_
4-35	578-586	approval	event[28]	new[28]	_	_
4-36	587-589	of	event[28]	new[28]	_	_
4-37	590-599	medicines	event[28]|substance	new[28]|new	_	_
4-38	600-601	,	_	_	_	_
4-39	602-607	added	_	_	_	_
4-40	608-615	aspects	abstract[30]	new[30]	_	_
4-41	616-618	of	abstract[30]	new[30]	_	_
4-42	619-629	continuous	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-43	630-643	manufacturing	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-44	644-646	to	abstract[30]|abstract[31]	new[30]|new[31]	_	_
4-45	647-652	their	abstract[30]|abstract[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
4-46	653-663	guidelines	abstract[30]|abstract[31]|abstract[32]	new[30]|new[31]|new[32]	_	_
4-47	664-665	,	_	_	_	_
4-48	666-673	whereas	time[33]	new[33]	_	_
4-49	674-677	for	time[33]	new[33]	_	_
4-50	678-679	a	time[33]	new[33]	_	_
4-51	680-684	long	time[33]	new[33]	_	_
4-52	685-689	time	time[33]	new[33]	_	_
4-53	690-693	the	abstract[34]	new[34]	_	_
4-54	694-699	focus	abstract[34]	new[34]	_	_
4-55	700-702	of	abstract[34]	new[34]	_	_
4-56	703-707	flow	abstract[34]|abstract|abstract[36]	new[34]|giv|giv[36]	coref|coref	4-63[37_36]|5-5
4-57	708-717	processes	abstract[34]|abstract[36]	new[34]|giv[36]	_	_
4-58	718-721	was	_	_	_	_
4-59	722-724	on	_	_	_	_
4-60	725-726	“	_	_	_	_
4-61	727-734	classic	_	_	_	_
4-62	735-736	”	_	_	_	_
4-63	737-745	chemical	abstract[37]	giv[37]	coref	5-5[42_37]
4-64	746-755	processes	abstract[37]	giv[37]	_	_
4-65	756-760	with	abstract[37]	giv[37]	_	_
4-66	761-762	,	abstract[37]	giv[37]	_	_
4-67	763-766	for	abstract[37]	giv[37]	_	_
4-68	767-774	example	abstract[37]	giv[37]	_	_
4-69	775-776	,	abstract[37]	giv[37]	_	_
4-70	777-786	hazardous	abstract[37]|substance[38]	giv[37]|new[38]	_	_
4-71	787-790	and	abstract[37]|substance[38]	giv[37]|new[38]	_	_
4-72	791-800	thermally	abstract[37]|substance[38]	giv[37]|new[38]	_	_
4-73	801-807	labile	abstract[37]|substance[38]	giv[37]|new[38]	_	_
4-74	808-818	substances	abstract[37]|substance[38]	giv[37]|new[38]	_	_
4-75	819-822	and	abstract[37]	giv[37]	_	_
4-76	823-837	chemocatalytic	abstract[37]|abstract[39]	giv[37]|new[39]	coref	13-12[109_39]
4-77	838-847	reactions	abstract[37]|abstract[39]	giv[37]|new[39]	_	_
4-78	848-849	.	_	_	_	_

#Text=Recently , biocatalysis in flow processes has become an emerging field with an increasing number of examples .
5-1	850-858	Recently	_	_	_	_
5-2	859-860	,	_	_	_	_
5-3	861-873	biocatalysis	abstract[40]	new[40]	coref	8-11[0_40]
5-4	874-876	in	abstract[40]	new[40]	_	_
5-5	877-881	flow	abstract[40]|abstract|abstract[42]	new[40]|giv|giv[42]	coref|coref	6-11|8-13[71_42]
5-6	882-891	processes	abstract[40]|abstract[42]	new[40]|giv[42]	_	_
5-7	892-895	has	_	_	_	_
5-8	896-902	become	_	_	_	_
5-9	903-905	an	_	_	_	_
5-10	906-914	emerging	_	_	_	_
5-11	915-920	field	_	_	_	_
5-12	921-925	with	_	_	_	_
5-13	926-928	an	abstract[43]	new[43]	_	_
5-14	929-939	increasing	abstract[43]	new[43]	_	_
5-15	940-946	number	abstract[43]	new[43]	_	_
5-16	947-949	of	abstract[43]	new[43]	_	_
5-17	950-958	examples	abstract[43]|abstract	new[43]|new	coref	6-31[57_0]
5-18	959-960	.	_	_	_	_

#Text=An enzymatic reaction of particular interest for an application in flow mode due to its matured technology level is asymmetric ketone reduction , having a proven track record underlined by many successful examples demonstrated in the past for the batch mode .
6-1	961-963	An	abstract[45]	new[45]	coref	6-20[54_45]
6-2	964-973	enzymatic	abstract[45]	new[45]	_	_
6-3	974-982	reaction	abstract[45]	new[45]	_	_
6-4	983-985	of	abstract[45]	new[45]	_	_
6-5	986-996	particular	abstract[45]|organization[46]	new[45]|giv[46]	_	_
6-6	997-1005	interest	abstract[45]|organization[46]	new[45]|giv[46]	_	_
6-7	1006-1009	for	abstract[45]|organization[46]	new[45]|giv[46]	_	_
6-8	1010-1012	an	abstract[45]|organization[46]|abstract[47]	new[45]|giv[46]|new[47]	coref	10-13[84_47]
6-9	1013-1024	application	abstract[45]|organization[46]|abstract[47]	new[45]|giv[46]|new[47]	_	_
6-10	1025-1027	in	abstract[45]|organization[46]|abstract[47]	new[45]|giv[46]|new[47]	_	_
6-11	1028-1032	flow	abstract[45]|organization[46]|abstract[47]|abstract|abstract[49]	new[45]|giv[46]|new[47]|giv|new[49]	ana|coref	6-15[0_49]|8-13
6-12	1033-1037	mode	abstract[45]|organization[46]|abstract[47]|abstract[49]	new[45]|giv[46]|new[47]|new[49]	_	_
6-13	1038-1041	due	_	_	_	_
6-14	1042-1044	to	_	_	_	_
6-15	1045-1048	its	abstract|abstract[52]	giv|new[52]	coref	6-39[60_0]
6-16	1049-1056	matured	abstract[52]	new[52]	_	_
6-17	1057-1067	technology	abstract|abstract[52]	new|new[52]	_	_
6-18	1068-1073	level	abstract[52]	new[52]	_	_
6-19	1074-1076	is	_	_	_	_
6-20	1077-1087	asymmetric	abstract[54]	giv[54]	coref	10-20[88_54]
6-21	1088-1094	ketone	substance|abstract[54]	new|giv[54]	coref	9-13
6-22	1095-1104	reduction	abstract[54]	giv[54]	_	_
6-23	1105-1106	,	_	_	_	_
6-24	1107-1113	having	_	_	_	_
6-25	1114-1115	a	abstract[56]	new[56]	_	_
6-26	1116-1122	proven	abstract[56]	new[56]	_	_
6-27	1123-1128	track	place|abstract[56]	new|new[56]	_	_
6-28	1129-1135	record	abstract[56]	new[56]	_	_
6-29	1136-1146	underlined	_	_	_	_
6-30	1147-1149	by	_	_	_	_
6-31	1150-1154	many	abstract[57]	giv[57]	coref	8-9[68_57]
6-32	1155-1165	successful	abstract[57]	giv[57]	_	_
6-33	1166-1174	examples	abstract[57]	giv[57]	_	_
6-34	1175-1187	demonstrated	_	_	_	_
6-35	1188-1190	in	_	_	_	_
6-36	1191-1194	the	time[58]	new[58]	_	_
6-37	1195-1199	past	time[58]	new[58]	_	_
6-38	1200-1203	for	time[58]	new[58]	_	_
6-39	1204-1207	the	time[58]|abstract[60]	new[58]|giv[60]	coref	10-24[89_60]
6-40	1208-1213	batch	time[58]|quantity|abstract[60]	new[58]|giv|giv[60]	_	_
6-41	1214-1218	mode	time[58]|abstract[60]	new[58]|giv[60]	_	_
6-42	1219-1220	.	_	_	_	_

#Text=Recently , significant process in the biocatalytic reductive synthesis of alcohols starting from ketones , as well as syntheses by non-enzymatic means , have been reported .
7-1	1221-1229	Recently	_	_	_	_
7-2	1230-1231	,	_	_	_	_
7-3	1232-1243	significant	event[61]	new[61]	coref	15-7[116_61]
7-4	1244-1251	process	event[61]	new[61]	_	_
7-5	1252-1254	in	event[61]	new[61]	_	_
7-6	1255-1258	the	event[61]|abstract[62]	new[61]|new[62]	_	_
7-7	1259-1271	biocatalytic	event[61]|abstract[62]	new[61]|new[62]	_	_
7-8	1272-1281	reductive	event[61]|abstract[62]	new[61]|new[62]	_	_
7-9	1282-1291	synthesis	event[61]|abstract[62]	new[61]|new[62]	_	_
7-10	1292-1294	of	event[61]|abstract[62]	new[61]|new[62]	_	_
7-11	1295-1303	alcohols	event[61]|abstract[62]|substance	new[61]|new[62]|new	_	_
7-12	1304-1312	starting	event[61]	new[61]	_	_
7-13	1313-1317	from	event[61]	new[61]	_	_
7-14	1318-1325	ketones	event[61]|substance	new[61]|new	_	_
7-15	1326-1327	,	event[61]	new[61]	_	_
7-16	1328-1330	as	event[61]	new[61]	_	_
7-17	1331-1335	well	event[61]	new[61]	_	_
7-18	1336-1338	as	event[61]	new[61]	_	_
7-19	1339-1348	syntheses	event[61]|abstract[65]	new[61]|new[65]	_	_
7-20	1349-1351	by	event[61]|abstract[65]	new[61]|new[65]	_	_
7-21	1352-1365	non-enzymatic	event[61]|abstract[65]	new[61]|new[65]	_	_
7-22	1366-1371	means	_	_	_	_
7-23	1372-1373	,	_	_	_	_
7-24	1374-1378	have	_	_	_	_
7-25	1379-1383	been	_	_	_	_
7-26	1384-1392	reported	_	_	_	_
7-27	1393-1394	.	_	_	_	_

#Text=In recent years , an increasing number of examples of biocatalysis in flow processes have been reported .
8-1	1395-1397	In	_	_	_	_
8-2	1398-1404	recent	time[66]	new[66]	_	_
8-3	1405-1410	years	time[66]	new[66]	_	_
8-4	1411-1412	,	_	_	_	_
8-5	1413-1415	an	abstract[67]	new[67]	_	_
8-6	1416-1426	increasing	abstract[67]	new[67]	_	_
8-7	1427-1433	number	abstract[67]	new[67]	_	_
8-8	1434-1436	of	abstract[67]	new[67]	_	_
8-9	1437-1445	examples	abstract[67]|abstract[68]	new[67]|giv[68]	_	_
8-10	1446-1448	of	abstract[67]|abstract[68]	new[67]|giv[68]	_	_
8-11	1449-1461	biocatalysis	abstract[67]|abstract[68]|abstract	new[67]|giv[68]|giv	_	_
8-12	1462-1464	in	abstract[67]|abstract[68]	new[67]|giv[68]	_	_
8-13	1465-1469	flow	abstract[67]|abstract[68]|abstract|abstract[71]	new[67]|giv[68]|giv|giv[71]	coref|coref	9-23|9-23[80_71]
8-14	1470-1479	processes	abstract[67]|abstract[68]|abstract[71]	new[67]|giv[68]|giv[71]	_	_
8-15	1480-1484	have	_	_	_	_
8-16	1485-1489	been	_	_	_	_
8-17	1490-1498	reported	_	_	_	_
8-18	1499-1500	.	_	_	_	_

#Text=Although only being studied to a minor extent , some examples of ketone reductions with an alcohol dehydrogenase ( ADH ) in flow processes have been described .
9-1	1501-1509	Although	_	_	_	_
9-2	1510-1514	only	_	_	_	_
9-3	1515-1520	being	_	_	_	_
9-4	1521-1528	studied	_	_	_	_
9-5	1529-1531	to	_	_	_	_
9-6	1532-1533	a	abstract[72]	new[72]	_	_
9-7	1534-1539	minor	abstract[72]	new[72]	_	_
9-8	1540-1546	extent	abstract[72]	new[72]	_	_
9-9	1547-1548	,	_	_	_	_
9-10	1549-1553	some	abstract[73]	new[73]	_	_
9-11	1554-1562	examples	abstract[73]	new[73]	_	_
9-12	1563-1565	of	abstract[73]	new[73]	_	_
9-13	1566-1572	ketone	abstract[73]|substance|abstract[75]	new[73]|giv|new[75]	coref	10-21
9-14	1573-1583	reductions	abstract[73]|abstract[75]	new[73]|new[75]	_	_
9-15	1584-1588	with	abstract[73]|abstract[75]	new[73]|new[75]	_	_
9-16	1589-1591	an	abstract[73]|abstract[75]|abstract[77]	new[73]|new[75]|new[77]	appos	9-20[0_77]
9-17	1592-1599	alcohol	abstract[73]|abstract[75]|substance|abstract[77]	new[73]|new[75]|new|new[77]	_	_
9-18	1600-1613	dehydrogenase	abstract[73]|abstract[75]|abstract[77]	new[73]|new[75]|new[77]	_	_
9-19	1614-1615	(	_	_	_	_
9-20	1616-1619	ADH	abstract	giv	coref	10-40[94_0]
9-21	1620-1621	)	_	_	_	_
9-22	1622-1624	in	_	_	_	_
9-23	1625-1629	flow	abstract|abstract[80]	giv|giv[80]	coref|coref	12-10|16-2[121_80]
9-24	1630-1639	processes	abstract[80]	giv[80]	_	_
9-25	1640-1644	have	_	_	_	_
9-26	1645-1649	been	_	_	_	_
9-27	1650-1659	described	_	_	_	_
9-28	1660-1661	.	_	_	_	_

#Text=For example , Wandrey ’s and Liese ’s groups studied in detail the application of enzyme membrane reactors for enzymatic ketone reduction in a continuously running mode , and packed bed reactor setups were described by further groups using carrier-bound ADH from Lactobacillus brevis ( LB-ADH ) in combination with a mobile aqueous phase , or magnetic nanoparticle-bound ADH .
10-1	1662-1665	For	_	_	_	_
10-2	1666-1673	example	_	_	_	_
10-3	1674-1675	,	_	_	_	_
10-4	1676-1683	Wandrey	person[81]|person[83]	new[81]|new[83]	coref	10-37[93_83]
10-5	1684-1686	’s	person[81]|person[83]	new[81]|new[83]	_	_
10-6	1687-1690	and	person[83]	new[83]	_	_
10-7	1691-1696	Liese	person[82]|person[83]	new[82]|new[83]	_	_
10-8	1697-1699	’s	person[82]|person[83]	new[82]|new[83]	_	_
10-9	1700-1706	groups	person[83]	new[83]	_	_
10-10	1707-1714	studied	_	_	_	_
10-11	1715-1717	in	_	_	_	_
10-12	1718-1724	detail	_	_	_	_
10-13	1725-1728	the	abstract[84]	giv[84]	coref	29-8[212_84]
10-14	1729-1740	application	abstract[84]	giv[84]	_	_
10-15	1741-1743	of	abstract[84]	giv[84]	_	_
10-16	1744-1750	enzyme	abstract[84]|object[86]	giv[84]|new[86]	coref	16-5[123_86]
10-17	1751-1759	membrane	abstract[84]|substance|object[86]	giv[84]|new|new[86]	_	_
10-18	1760-1768	reactors	abstract[84]|object[86]	giv[84]|new[86]	_	_
10-19	1769-1772	for	abstract[84]|object[86]	giv[84]|new[86]	_	_
10-20	1773-1782	enzymatic	abstract[84]|object[86]|abstract[88]	giv[84]|new[86]|giv[88]	coref	14-9[0_88]
10-21	1783-1789	ketone	abstract[84]|object[86]|substance|abstract[88]	giv[84]|new[86]|giv|giv[88]	_	_
10-22	1790-1799	reduction	abstract[84]|object[86]|abstract[88]	giv[84]|new[86]|giv[88]	_	_
10-23	1800-1802	in	abstract[84]|object[86]|abstract[88]	giv[84]|new[86]|giv[88]	_	_
10-24	1803-1804	a	abstract[84]|object[86]|abstract[88]|abstract[89]	giv[84]|new[86]|giv[88]|giv[89]	_	_
10-25	1805-1817	continuously	abstract[84]|object[86]|abstract[88]|abstract[89]	giv[84]|new[86]|giv[88]|giv[89]	_	_
10-26	1818-1825	running	abstract[84]|object[86]|abstract[88]|abstract[89]	giv[84]|new[86]|giv[88]|giv[89]	_	_
10-27	1826-1830	mode	abstract[84]|object[86]|abstract[88]|abstract[89]	giv[84]|new[86]|giv[88]|giv[89]	_	_
10-28	1831-1832	,	_	_	_	_
10-29	1833-1836	and	_	_	_	_
10-30	1837-1843	packed	_	_	_	_
10-31	1844-1847	bed	object|abstract[92]	new|new[92]	coref	16-6
10-32	1848-1855	reactor	object|abstract[92]	new|new[92]	coref	29-11[214_0]
10-33	1856-1862	setups	abstract[92]	new[92]	_	_
10-34	1863-1867	were	_	_	_	_
10-35	1868-1877	described	_	_	_	_
10-36	1878-1880	by	_	_	_	_
10-37	1881-1888	further	person[93]	giv[93]	_	_
10-38	1889-1895	groups	person[93]	giv[93]	_	_
10-39	1896-1901	using	_	_	_	_
10-40	1902-1915	carrier-bound	abstract[94]	giv[94]	coref	10-57[99_94]
10-41	1916-1919	ADH	abstract[94]	giv[94]	_	_
10-42	1920-1924	from	_	_	_	_
10-43	1925-1938	Lactobacillus	abstract	new	_	_
10-44	1939-1945	brevis	_	_	_	_
10-45	1946-1947	(	_	_	_	_
10-46	1948-1954	LB-ADH	abstract	new	coref	38-10
10-47	1955-1956	)	_	_	_	_
10-48	1957-1959	in	_	_	_	_
10-49	1960-1971	combination	abstract[97]	new[97]	_	_
10-50	1972-1976	with	abstract[97]	new[97]	_	_
10-51	1977-1978	a	abstract[97]|abstract[98]	new[97]|new[98]	coref	29-29[0_98]
10-52	1979-1985	mobile	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-53	1986-1993	aqueous	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-54	1994-1999	phase	abstract[97]|abstract[98]	new[97]|new[98]	_	_
10-55	2000-2001	,	abstract[97]	new[97]	_	_
10-56	2002-2004	or	abstract[97]	new[97]	_	_
10-57	2005-2013	magnetic	abstract[97]|abstract[99]	new[97]|giv[99]	coref	12-6[0_99]
10-58	2014-2032	nanoparticle-bound	abstract[97]|abstract[99]	new[97]|giv[99]	_	_
10-59	2033-2036	ADH	abstract[97]|abstract[99]	new[97]|giv[99]	_	_
10-60	2037-2038	.	_	_	_	_

#Text=In addition , Buehler et al.
11-1	2039-2041	In	_	_	_	_
11-2	2042-2050	addition	_	_	_	_
11-3	2051-2052	,	_	_	_	_
11-4	2053-2060	Buehler	person	new	_	_
11-5	2061-2063	et	_	_	_	_
11-6	2064-2067	al.	_	_	_	_

#Text=investigated intensively the use of ADH in aqueous/organic segmented flow systems .
12-1	2068-2080	investigated	_	_	_	_
12-2	2081-2092	intensively	_	_	_	_
12-3	2093-2096	the	abstract[101]	new[101]	ana	13-1[0_101]
12-4	2097-2100	use	abstract[101]	new[101]	_	_
12-5	2101-2103	of	abstract[101]	new[101]	_	_
12-6	2104-2107	ADH	abstract[101]|abstract	new[101]|giv	coref	27-5[198_0]
12-7	2108-2110	in	abstract[101]	new[101]	_	_
12-8	2111-2126	aqueous/organic	abstract[101]|abstract[104]	new[101]|new[104]	_	_
12-9	2127-2136	segmented	abstract[101]|abstract[104]	new[101]|new[104]	_	_
12-10	2137-2141	flow	abstract[101]|abstract|abstract[104]	new[101]|giv|new[104]	coref	15-17
12-11	2142-2149	systems	abstract[101]|abstract[104]	new[101]|new[104]	_	_
12-12	2150-2151	.	_	_	_	_

#Text=It was shown that emulsion formation could be eliminated , and enzymatic mass transfer-limited reactions can be enhanced .
13-1	2152-2154	It	abstract	giv	_	_
13-2	2155-2158	was	_	_	_	_
13-3	2159-2164	shown	_	_	_	_
13-4	2165-2169	that	_	_	_	_
13-5	2170-2178	emulsion	substance|abstract[107]	new|new[107]	_	_
13-6	2179-2188	formation	abstract[107]	new[107]	_	_
13-7	2189-2194	could	_	_	_	_
13-8	2195-2197	be	_	_	_	_
13-9	2198-2208	eliminated	_	_	_	_
13-10	2209-2210	,	_	_	_	_
13-11	2211-2214	and	_	_	_	_
13-12	2215-2224	enzymatic	abstract[109]	giv[109]	_	_
13-13	2225-2229	mass	quantity|abstract[109]	new|giv[109]	coref	29-25
13-14	2230-2246	transfer-limited	abstract[109]	giv[109]	_	_
13-15	2247-2256	reactions	abstract[109]	giv[109]	_	_
13-16	2257-2260	can	_	_	_	_
13-17	2261-2263	be	_	_	_	_
13-18	2264-2272	enhanced	_	_	_	_
13-19	2273-2274	.	_	_	_	_

#Text=Furthermore , different means of stabilization of this reaction system were investigated .
14-1	2275-2286	Furthermore	_	_	_	_
14-2	2287-2288	,	_	_	_	_
14-3	2289-2298	different	abstract[110]	new[110]	_	_
14-4	2299-2304	means	abstract[110]	new[110]	_	_
14-5	2305-2307	of	abstract[110]	new[110]	_	_
14-6	2308-2321	stabilization	abstract[110]|abstract[111]	new[110]|new[111]	_	_
14-7	2322-2324	of	abstract[110]|abstract[111]	new[110]|new[111]	_	_
14-8	2325-2329	this	abstract[110]|abstract[111]|abstract[113]	new[110]|new[111]|new[113]	_	_
14-9	2330-2338	reaction	abstract[110]|abstract[111]|abstract|abstract[113]	new[110]|new[111]|giv|new[113]	_	_
14-10	2339-2345	system	abstract[110]|abstract[111]|abstract[113]	new[110]|new[111]|new[113]	_	_
14-11	2346-2350	were	_	_	_	_
14-12	2351-2363	investigated	_	_	_	_
14-13	2364-2365	.	_	_	_	_

#Text=Very recently , our group published an improved downstream process by means of such a segmented flow process , illustrated using two different ADHs and substrates .
15-1	2366-2370	Very	_	_	_	_
15-2	2371-2379	recently	_	_	_	_
15-3	2380-2381	,	_	_	_	_
15-4	2382-2385	our	person|organization[115]	acc|new[115]	_	_
15-5	2386-2391	group	organization[115]	new[115]	_	_
15-6	2392-2401	published	_	_	_	_
15-7	2402-2404	an	event[116]	giv[116]	coref	15-14[118_116]
15-8	2405-2413	improved	event[116]	giv[116]	_	_
15-9	2414-2424	downstream	event[116]	giv[116]	_	_
15-10	2425-2432	process	event[116]	giv[116]	_	_
15-11	2433-2435	by	_	_	_	_
15-12	2436-2441	means	_	_	_	_
15-13	2442-2444	of	_	_	_	_
15-14	2445-2449	such	event[118]	giv[118]	coref	19-11[140_118]
15-15	2450-2451	a	event[118]	giv[118]	_	_
15-16	2452-2461	segmented	event[118]	giv[118]	_	_
15-17	2462-2466	flow	abstract|event[118]	giv|giv[118]	_	_
15-18	2467-2474	process	event[118]	giv[118]	_	_
15-19	2475-2476	,	_	_	_	_
15-20	2477-2488	illustrated	_	_	_	_
15-21	2489-2494	using	_	_	_	_
15-22	2495-2498	two	abstract[119]	new[119]	coref	26-11[0_119]
15-23	2499-2508	different	abstract[119]	new[119]	_	_
15-24	2509-2513	ADHs	abstract[119]	new[119]	_	_
15-25	2514-2517	and	_	_	_	_
15-26	2518-2528	substrates	object	new	_	_
15-27	2529-2530	.	_	_	_	_

#Text=In continuous processes using packed bed reactors ( PBR ) , catalyst immobilization is a prerequisite .
16-1	2531-2533	In	_	_	_	_
16-2	2534-2544	continuous	abstract[121]	giv[121]	coref	17-3[128_121]
16-3	2545-2554	processes	abstract[121]	giv[121]	_	_
16-4	2555-2560	using	_	_	_	_
16-5	2561-2567	packed	object[123]	giv[123]	appos	16-9[0_123]
16-6	2568-2571	bed	place|object[123]	giv|giv[123]	coref	29-13
16-7	2572-2580	reactors	object[123]	giv[123]	_	_
16-8	2581-2582	(	_	_	_	_
16-9	2583-2586	PBR	object	giv	_	_
16-10	2587-2588	)	_	_	_	_
16-11	2589-2590	,	_	_	_	_
16-12	2591-2599	catalyst	abstract|abstract[126]	new|new[126]	coref|coref	16-15[127_126]|17-16[132_0]
16-13	2600-2614	immobilization	abstract[126]	new[126]	_	_
16-14	2615-2617	is	_	_	_	_
16-15	2618-2619	a	abstract[127]	giv[127]	coref	17-7[0_127]
16-16	2620-2632	prerequisite	abstract[127]	giv[127]	_	_
16-17	2633-2634	.	_	_	_	_

#Text=Also , downstream processes benefit from immobilization , as separation of the reaction mixture from the catalyst is easier , and the catalyst reusability is improved .
17-1	2635-2639	Also	_	_	_	_
17-2	2640-2641	,	_	_	_	_
17-3	2642-2652	downstream	abstract[128]	giv[128]	_	_
17-4	2653-2662	processes	abstract[128]	giv[128]	_	_
17-5	2663-2670	benefit	_	_	_	_
17-6	2671-2675	from	_	_	_	_
17-7	2676-2690	immobilization	abstract	giv	coref	19-12
17-8	2691-2692	,	_	_	_	_
17-9	2693-2695	as	_	_	_	_
17-10	2696-2706	separation	event[130]	new[130]	_	_
17-11	2707-2709	of	event[130]	new[130]	_	_
17-12	2710-2713	the	event[130]|substance[131]	new[130]|new[131]	_	_
17-13	2714-2722	reaction	event[130]|substance[131]	new[130]|new[131]	_	_
17-14	2723-2730	mixture	event[130]|substance[131]	new[130]|new[131]	_	_
17-15	2731-2735	from	event[130]|substance[131]	new[130]|new[131]	_	_
17-16	2736-2739	the	event[130]|substance[131]|abstract[132]	new[130]|new[131]|giv[132]	coref	18-13[136_132]
17-17	2740-2748	catalyst	event[130]|substance[131]|abstract[132]	new[130]|new[131]|giv[132]	_	_
17-18	2749-2751	is	_	_	_	_
17-19	2752-2758	easier	_	_	_	_
17-20	2759-2760	,	_	_	_	_
17-21	2761-2764	and	_	_	_	_
17-22	2765-2768	the	abstract[133]	new[133]	_	_
17-23	2769-2777	catalyst	abstract[133]	new[133]	_	_
17-24	2778-2789	reusability	abstract[133]	new[133]	_	_
17-25	2790-2792	is	_	_	_	_
17-26	2793-2801	improved	_	_	_	_
17-27	2802-2803	.	_	_	_	_

#Text=Moreover , both , operational , as well as storage stability of the catalyst can potentially be significantly increased .
18-1	2804-2812	Moreover	_	_	_	_
18-2	2813-2814	,	_	_	_	_
18-3	2815-2819	both	_	_	_	_
18-4	2820-2821	,	_	_	_	_
18-5	2822-2833	operational	_	_	_	_
18-6	2834-2835	,	_	_	_	_
18-7	2836-2838	as	_	_	_	_
18-8	2839-2843	well	_	_	_	_
18-9	2844-2846	as	_	_	_	_
18-10	2847-2854	storage	place|abstract[135]	new|new[135]	_	_
18-11	2855-2864	stability	abstract[135]	new[135]	_	_
18-12	2865-2867	of	abstract[135]	new[135]	_	_
18-13	2868-2871	the	abstract[135]|object[136]	new[135]|giv[136]	coref	19-23[143_136]
18-14	2872-2880	catalyst	abstract[135]|object[136]	new[135]|giv[136]	_	_
18-15	2881-2884	can	_	_	_	_
18-16	2885-2896	potentially	_	_	_	_
18-17	2897-2899	be	_	_	_	_
18-18	2900-2913	significantly	_	_	_	_
18-19	2914-2923	increased	_	_	_	_
18-20	2924-2925	.	_	_	_	_

#Text=However , often a significant loss of enzymatic activity during the immobilization process represents a drawback , and the reproducible production of immobilized catalyst may be a further challenge .
19-1	2926-2933	However	_	_	_	_
19-2	2934-2935	,	_	_	_	_
19-3	2936-2941	often	_	_	_	_
19-4	2942-2943	a	abstract[137]	new[137]	coref	27-18[201_137]
19-5	2944-2955	significant	abstract[137]	new[137]	_	_
19-6	2956-2960	loss	abstract[137]	new[137]	_	_
19-7	2961-2963	of	abstract[137]	new[137]	_	_
19-8	2964-2973	enzymatic	abstract[137]|abstract[138]	new[137]|new[138]	coref	27-22[0_138]
19-9	2974-2982	activity	abstract[137]|abstract[138]	new[137]|new[138]	_	_
19-10	2983-2989	during	abstract[137]|abstract[138]	new[137]|new[138]	_	_
19-11	2990-2993	the	abstract[137]|abstract[138]|event[140]	new[137]|new[138]|giv[140]	_	_
19-12	2994-3008	immobilization	abstract[137]|abstract[138]|abstract|event[140]	new[137]|new[138]|giv|giv[140]	coref	21-9[166_0]
19-13	3009-3016	process	abstract[137]|abstract[138]|event[140]	new[137]|new[138]|giv[140]	_	_
19-14	3017-3027	represents	_	_	_	_
19-15	3028-3029	a	abstract[141]	new[141]	_	_
19-16	3030-3038	drawback	abstract[141]	new[141]	_	_
19-17	3039-3040	,	_	_	_	_
19-18	3041-3044	and	_	_	_	_
19-19	3045-3048	the	abstract[142]	new[142]	coref	19-27[144_142]
19-20	3049-3061	reproducible	abstract[142]	new[142]	_	_
19-21	3062-3072	production	abstract[142]	new[142]	_	_
19-22	3073-3075	of	abstract[142]	new[142]	_	_
19-23	3076-3087	immobilized	abstract[142]|abstract[143]	new[142]|giv[143]	coref	28-23[0_143]
19-24	3088-3096	catalyst	abstract[142]|abstract[143]	new[142]|giv[143]	_	_
19-25	3097-3100	may	_	_	_	_
19-26	3101-3103	be	_	_	_	_
19-27	3104-3105	a	abstract[144]	giv[144]	_	_
19-28	3106-3113	further	abstract[144]	giv[144]	_	_
19-29	3114-3123	challenge	abstract[144]	giv[144]	_	_
19-30	3124-3125	.	_	_	_	_

#Text=Numerous techniques have been developed over the past years , which can be classified in the following three major methods : ( a ) binding to a solid support ( carrier ) , ( b ) entrapment ( encapsulation ) in polymer networks , or ( c ) cross-linking in the form of cross-linked enzyme aggregates ( CLEAs ) or cross-linked enzyme crystals ( CLECs ) .
20-1	3126-3134	Numerous	abstract[145]	new[145]	_	_
20-2	3135-3145	techniques	abstract[145]	new[145]	_	_
20-3	3146-3150	have	_	_	_	_
20-4	3151-3155	been	_	_	_	_
20-5	3156-3165	developed	_	_	_	_
20-6	3166-3170	over	_	_	_	_
20-7	3171-3174	the	time[146]	new[146]	_	_
20-8	3175-3179	past	time[146]	new[146]	_	_
20-9	3180-3185	years	time[146]	new[146]	_	_
20-10	3186-3187	,	_	_	_	_
20-11	3188-3193	which	_	_	_	_
20-12	3194-3197	can	_	_	_	_
20-13	3198-3200	be	_	_	_	_
20-14	3201-3211	classified	_	_	_	_
20-15	3212-3214	in	_	_	_	_
20-16	3215-3218	the	abstract[147]	new[147]	_	_
20-17	3219-3228	following	abstract[147]	new[147]	_	_
20-18	3229-3234	three	abstract[147]	new[147]	_	_
20-19	3235-3240	major	abstract[147]	new[147]	_	_
20-20	3241-3248	methods	abstract[147]	new[147]	_	_
20-21	3249-3250	:	abstract[147]	new[147]	_	_
20-22	3251-3252	(	abstract[147]	new[147]	_	_
20-23	3253-3254	a	abstract[147]	new[147]	_	_
20-24	3255-3256	)	abstract[147]	new[147]	_	_
20-25	3257-3264	binding	_	_	_	_
20-26	3265-3267	to	_	_	_	_
20-27	3268-3269	a	abstract[148]	new[148]	coref	25-22[189_148]
20-28	3270-3275	solid	abstract[148]	new[148]	_	_
20-29	3276-3283	support	abstract[148]	new[148]	_	_
20-30	3284-3285	(	_	_	_	_
20-31	3286-3293	carrier	organization	new	_	_
20-32	3294-3295	)	_	_	_	_
20-33	3296-3297	,	_	_	_	_
20-34	3298-3299	(	_	_	_	_
20-35	3300-3301	b	abstract	new	appos	20-39
20-36	3302-3303	)	_	_	_	_
20-37	3304-3314	entrapment	abstract	new	coref	22-8[169_0]
20-38	3315-3316	(	_	_	_	_
20-39	3317-3330	encapsulation	abstract	giv	_	_
20-40	3331-3332	)	_	_	_	_
20-41	3333-3335	in	_	_	_	_
20-42	3336-3343	polymer	person|place[154]	new|new[154]	coref|coref	22-12|22-12[172_154]
20-43	3344-3352	networks	place[154]	new[154]	_	_
20-44	3353-3354	,	_	_	_	_
20-45	3355-3357	or	_	_	_	_
20-46	3358-3359	(	_	_	_	_
20-47	3360-3361	c	abstract	new	_	_
20-48	3362-3363	)	_	_	_	_
20-49	3364-3377	cross-linking	_	_	_	_
20-50	3378-3380	in	_	_	_	_
20-51	3381-3384	the	substance[156]	new[156]	coref	26-21[196_156]
20-52	3385-3389	form	substance[156]	new[156]	_	_
20-53	3390-3392	of	substance[156]	new[156]	_	_
20-54	3393-3405	cross-linked	substance[156]|abstract[158]	new[156]|new[158]	appos	20-58[0_158]
20-55	3406-3412	enzyme	substance[156]|substance|abstract[158]	new[156]|new|new[158]	coref	20-62
20-56	3413-3423	aggregates	substance[156]|abstract[158]	new[156]|new[158]	_	_
20-57	3424-3425	(	_	_	_	_
20-58	3426-3431	CLEAs	abstract	giv	_	_
20-59	3432-3433	)	_	_	_	_
20-60	3434-3436	or	_	_	_	_
20-61	3437-3449	cross-linked	object[161]	new[161]	_	_
20-62	3450-3456	enzyme	substance|object[161]	giv|new[161]	coref	21-9
20-63	3457-3465	crystals	object[161]	new[161]	_	_
20-64	3466-3467	(	_	_	_	_
20-65	3468-3473	CLECs	abstract	new	_	_
20-66	3474-3475	)	_	_	_	_
20-67	3476-3477	.	_	_	_	_

#Text=Recently , much progress in the field of enzyme immobilization has been made .
21-1	3478-3486	Recently	_	_	_	_
21-2	3487-3488	,	_	_	_	_
21-3	3489-3493	much	abstract[163]	new[163]	_	_
21-4	3494-3502	progress	abstract[163]	new[163]	_	_
21-5	3503-3505	in	abstract[163]	new[163]	_	_
21-6	3506-3509	the	abstract[163]|abstract[164]	new[163]|new[164]	_	_
21-7	3510-3515	field	abstract[163]|abstract[164]	new[163]|new[164]	_	_
21-8	3516-3518	of	abstract[163]|abstract[164]	new[163]|new[164]	_	_
21-9	3519-3525	enzyme	abstract[163]|abstract[164]|substance|abstract[166]	new[163]|new[164]|giv|giv[166]	coref|coref	25-5[183_0]|28-13[0_166]
21-10	3526-3540	immobilization	abstract[163]|abstract[164]|abstract[166]	new[163]|new[164]|giv[166]	_	_
21-11	3541-3544	has	_	_	_	_
21-12	3545-3549	been	_	_	_	_
21-13	3550-3554	made	_	_	_	_
21-14	3555-3556	.	_	_	_	_

#Text=In this work , the option of entrapment of enzymes in polymer networks has been chosen .
22-1	3557-3559	In	_	_	_	_
22-2	3560-3564	this	abstract[167]	new[167]	_	_
22-3	3565-3569	work	abstract[167]	new[167]	_	_
22-4	3570-3571	,	_	_	_	_
22-5	3572-3575	the	abstract[168]	new[168]	_	_
22-6	3576-3582	option	abstract[168]	new[168]	_	_
22-7	3583-3585	of	abstract[168]	new[168]	_	_
22-8	3586-3596	entrapment	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
22-9	3597-3599	of	abstract[168]|abstract[169]	new[168]|giv[169]	_	_
22-10	3600-3607	enzymes	abstract[168]|abstract[169]|substance[170]	new[168]|giv[169]|new[170]	_	_
22-11	3608-3610	in	abstract[168]|abstract[169]|substance[170]	new[168]|giv[169]|new[170]	_	_
22-12	3611-3618	polymer	abstract[168]|abstract[169]|substance[170]|person|place[172]	new[168]|giv[169]|new[170]|giv|giv[172]	coref	30-1[223_0]
22-13	3619-3627	networks	abstract[168]|abstract[169]|substance[170]|place[172]	new[168]|giv[169]|new[170]|giv[172]	_	_
22-14	3628-3631	has	_	_	_	_
22-15	3632-3636	been	_	_	_	_
22-16	3637-3643	chosen	_	_	_	_
22-17	3644-3645	.	_	_	_	_

#Text=Often for this purpose , organic polymers containing cavities , sol-gel-processed particles , or membranes are used .
23-1	3646-3651	Often	_	_	_	_
23-2	3652-3655	for	_	_	_	_
23-3	3656-3660	this	abstract[173]	new[173]	_	_
23-4	3661-3668	purpose	abstract[173]	new[173]	_	_
23-5	3669-3670	,	_	_	_	_
23-6	3671-3678	organic	substance[174]	new[174]	coref	24-8[180_174]
23-7	3679-3687	polymers	substance[174]	new[174]	_	_
23-8	3688-3698	containing	_	_	_	_
23-9	3699-3707	cavities	object	new	_	_
23-10	3708-3709	,	_	_	_	_
23-11	3710-3727	sol-gel-processed	object[176]	new[176]	_	_
23-12	3728-3737	particles	object[176]	new[176]	_	_
23-13	3738-3739	,	_	_	_	_
23-14	3740-3742	or	_	_	_	_
23-15	3743-3752	membranes	object	new	_	_
23-16	3753-3756	are	_	_	_	_
23-17	3757-3761	used	_	_	_	_
23-18	3762-3763	.	_	_	_	_

#Text=A special case is the use of superabsorbent polymers to immobilize the entire aqueous phase. .
24-1	3764-3765	A	abstract[178]	new[178]	coref	24-5[179_178]
24-2	3766-3773	special	abstract[178]	new[178]	_	_
24-3	3774-3778	case	abstract[178]	new[178]	_	_
24-4	3779-3781	is	_	_	_	_
24-5	3782-3785	the	abstract[179]	giv[179]	coref	25-2[182_179]
24-6	3786-3789	use	abstract[179]	giv[179]	_	_
24-7	3790-3792	of	abstract[179]	giv[179]	_	_
24-8	3793-3807	superabsorbent	abstract[179]|substance[180]	giv[179]|giv[180]	_	_
24-9	3808-3816	polymers	abstract[179]|substance[180]	giv[179]|giv[180]	_	_
24-10	3817-3819	to	_	_	_	_
24-11	3820-3830	immobilize	_	_	_	_
24-12	3831-3834	the	substance[181]	new[181]	_	_
24-13	3835-3841	entire	substance[181]	new[181]	_	_
24-14	3842-3849	aqueous	substance[181]	new[181]	_	_
24-15	3850-3856	phase.	substance[181]	new[181]	_	_
24-16	3857-3858	.	_	_	_	_

#Text=In this case , the enzyme is immobilized in its native aqueous environment , whereby undesired interactions of protein moieties with the support can be prevented .
25-1	3859-3861	In	_	_	_	_
25-2	3862-3866	this	abstract[182]	giv[182]	ana	25-10[0_182]
25-3	3867-3871	case	abstract[182]	giv[182]	_	_
25-4	3872-3873	,	_	_	_	_
25-5	3874-3877	the	substance[183]	giv[183]	coref	35-6[246_183]
25-6	3878-3884	enzyme	substance[183]	giv[183]	_	_
25-7	3885-3887	is	_	_	_	_
25-8	3888-3899	immobilized	_	_	_	_
25-9	3900-3902	in	_	_	_	_
25-10	3903-3906	its	abstract|place[185]	giv|new[185]	_	_
25-11	3907-3913	native	place[185]	new[185]	_	_
25-12	3914-3921	aqueous	place[185]	new[185]	_	_
25-13	3922-3933	environment	place[185]	new[185]	_	_
25-14	3934-3935	,	_	_	_	_
25-15	3936-3943	whereby	_	_	_	_
25-16	3944-3953	undesired	abstract[186]	new[186]	_	_
25-17	3954-3966	interactions	abstract[186]	new[186]	_	_
25-18	3967-3969	of	abstract[186]	new[186]	_	_
25-19	3970-3977	protein	abstract[186]|substance|substance[188]	new[186]|new|new[188]	coref|coref	31-21[231_188]|31-30[235_0]
25-20	3978-3986	moieties	abstract[186]|substance[188]	new[186]|new[188]	_	_
25-21	3987-3991	with	abstract[186]|substance[188]	new[186]|new[188]	_	_
25-22	3992-3995	the	abstract[186]|substance[188]|abstract[189]	new[186]|new[188]|giv[189]	_	_
25-23	3996-4003	support	abstract[186]|substance[188]|abstract[189]	new[186]|new[188]|giv[189]	_	_
25-24	4004-4007	can	_	_	_	_
25-25	4008-4010	be	_	_	_	_
25-26	4011-4020	prevented	_	_	_	_
25-27	4021-4022	.	_	_	_	_

#Text=Recently , Gröger et al. applied a method of immobilizing ADHs with superabsorber efficiently for the synthesis of diols in enantiomerically pure form .
26-1	4023-4031	Recently	_	_	_	_
26-2	4032-4033	,	_	_	_	_
26-3	4034-4040	Gröger	person	new	_	_
26-4	4041-4043	et	_	_	_	_
26-5	4044-4047	al.	_	_	_	_
26-6	4048-4055	applied	_	_	_	_
26-7	4056-4057	a	abstract[191]	new[191]	coref	28-3[204_191]
26-8	4058-4064	method	abstract[191]	new[191]	_	_
26-9	4065-4067	of	_	_	_	_
26-10	4068-4080	immobilizing	_	_	_	_
26-11	4081-4085	ADHs	abstract	giv	_	_
26-12	4086-4090	with	_	_	_	_
26-13	4091-4104	superabsorber	substance	new	coref	33-13
26-14	4105-4116	efficiently	_	_	_	_
26-15	4117-4120	for	_	_	_	_
26-16	4121-4124	the	event[194]	new[194]	_	_
26-17	4125-4134	synthesis	event[194]	new[194]	_	_
26-18	4135-4137	of	event[194]	new[194]	_	_
26-19	4138-4143	diols	event[194]|substance[195]	new[194]|new[195]	_	_
26-20	4144-4146	in	event[194]|substance[195]	new[194]|new[195]	_	_
26-21	4147-4163	enantiomerically	event[194]|substance[195]|substance[196]	new[194]|new[195]|giv[196]	_	_
26-22	4164-4168	pure	event[194]|substance[195]|substance[196]	new[194]|new[195]|giv[196]	_	_
26-23	4169-4173	form	event[194]|substance[195]|substance[196]	new[194]|new[195]|giv[196]	_	_
26-24	4174-4175	.	_	_	_	_

#Text=In this example , the immobilized ADH from Rhodococcus sp . was used in organic solvents without a major loss in activity .
27-1	4176-4178	In	_	_	_	_
27-2	4179-4183	this	abstract[197]	new[197]	_	_
27-3	4184-4191	example	abstract[197]	new[197]	_	_
27-4	4192-4193	,	_	_	_	_
27-5	4194-4197	the	abstract[198]	giv[198]	coref	38-5[254_198]
27-6	4198-4209	immobilized	abstract[198]	giv[198]	_	_
27-7	4210-4213	ADH	abstract[198]	giv[198]	_	_
27-8	4214-4218	from	abstract[198]	giv[198]	_	_
27-9	4219-4230	Rhodococcus	abstract[198]|abstract[199]	giv[198]|new[199]	_	_
27-10	4231-4233	sp	abstract[198]|abstract[199]	giv[198]|new[199]	_	_
27-11	4234-4235	.	_	_	_	_
27-12	4236-4239	was	_	_	_	_
27-13	4240-4244	used	_	_	_	_
27-14	4245-4247	in	_	_	_	_
27-15	4248-4255	organic	substance[200]	new[200]	coref	40-7[266_200]
27-16	4256-4264	solvents	substance[200]	new[200]	_	_
27-17	4265-4272	without	_	_	_	_
27-18	4273-4274	a	abstract[201]	giv[201]	_	_
27-19	4275-4280	major	abstract[201]	giv[201]	_	_
27-20	4281-4285	loss	abstract[201]	giv[201]	_	_
27-21	4286-4288	in	abstract[201]	giv[201]	_	_
27-22	4289-4297	activity	abstract[201]|abstract	giv[201]|giv	_	_
27-23	4298-4299	.	_	_	_	_

#Text=Advantages of this method is the low cost , the very fast immobilization procedure ( <30 min ) , and the excellent catalyst reusability .
28-1	4300-4310	Advantages	abstract[203]	new[203]	coref	28-6[205_203]
28-2	4311-4313	of	abstract[203]	new[203]	_	_
28-3	4314-4318	this	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
28-4	4319-4325	method	abstract[203]|abstract[204]	new[203]|giv[204]	_	_
28-5	4326-4328	is	_	_	_	_
28-6	4329-4332	the	abstract[205]	giv[205]	appos	28-10[207_205]
28-7	4333-4336	low	abstract[205]	giv[205]	_	_
28-8	4337-4341	cost	abstract[205]	giv[205]	_	_
28-9	4342-4343	,	_	_	_	_
28-10	4344-4347	the	abstract[207]	giv[207]	appos	28-21[210_207]
28-11	4348-4352	very	abstract[207]	giv[207]	_	_
28-12	4353-4357	fast	abstract[207]	giv[207]	_	_
28-13	4358-4372	immobilization	abstract|abstract[207]	giv|giv[207]	_	_
28-14	4373-4382	procedure	abstract[207]	giv[207]	_	_
28-15	4383-4384	(	_	_	_	_
28-16	4385-4388	<30	time[208]	new[208]	_	_
28-17	4389-4392	min	time[208]	new[208]	_	_
28-18	4393-4394	)	_	_	_	_
28-19	4395-4396	,	_	_	_	_
28-20	4397-4400	and	_	_	_	_
28-21	4401-4404	the	abstract[210]	giv[210]	_	_
28-22	4405-4414	excellent	abstract[210]	giv[210]	_	_
28-23	4415-4423	catalyst	abstract|abstract[210]	giv|giv[210]	coref	38-17[256_0]
28-24	4424-4435	reusability	abstract[210]	giv[210]	_	_
28-25	4436-4437	.	_	_	_	_

#Text=Challenging , in particular with respect to an application in a fixed bed reactor , might be the gel-like consistency of the hydrogel and mass transfer limitations through phase interfaces in general .
29-1	4438-4449	Challenging	_	_	_	_
29-2	4450-4451	,	_	_	_	_
29-3	4452-4454	in	_	_	_	_
29-4	4455-4465	particular	_	_	_	_
29-5	4466-4470	with	_	_	_	_
29-6	4471-4478	respect	abstract[211]	new[211]	_	_
29-7	4479-4481	to	abstract[211]	new[211]	_	_
29-8	4482-4484	an	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
29-9	4485-4496	application	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
29-10	4497-4499	in	abstract[211]|abstract[212]	new[211]|giv[212]	_	_
29-11	4500-4501	a	abstract[211]|abstract[212]|object[214]	new[211]|giv[212]|giv[214]	_	_
29-12	4502-4507	fixed	abstract[211]|abstract[212]|object[214]	new[211]|giv[212]|giv[214]	_	_
29-13	4508-4511	bed	abstract[211]|abstract[212]|place|object[214]	new[211]|giv[212]|giv|giv[214]	_	_
29-14	4512-4519	reactor	abstract[211]|abstract[212]|object[214]	new[211]|giv[212]|giv[214]	_	_
29-15	4520-4521	,	_	_	_	_
29-16	4522-4527	might	_	_	_	_
29-17	4528-4530	be	_	_	_	_
29-18	4531-4534	the	abstract[215]	new[215]	_	_
29-19	4535-4543	gel-like	abstract[215]	new[215]	_	_
29-20	4544-4555	consistency	abstract[215]	new[215]	_	_
29-21	4556-4558	of	abstract[215]	new[215]	_	_
29-22	4559-4562	the	abstract[215]|substance[216]	new[215]|new[216]	_	_
29-23	4563-4571	hydrogel	abstract[215]|substance[216]	new[215]|new[216]	_	_
29-24	4572-4575	and	abstract[215]	new[215]	_	_
29-25	4576-4580	mass	abstract[215]|quantity|abstract[219]	new[215]|giv|new[219]	_	_
29-26	4581-4589	transfer	abstract[215]|abstract|abstract[219]	new[215]|new|new[219]	_	_
29-27	4590-4601	limitations	abstract[215]|abstract[219]	new[215]|new[219]	_	_
29-28	4602-4609	through	abstract[215]|abstract[219]	new[215]|new[219]	_	_
29-29	4610-4615	phase	abstract[215]|abstract[219]|abstract|abstract[221]	new[215]|new[219]|giv|new[221]	_	_
29-30	4616-4626	interfaces	abstract[215]|abstract[219]|abstract[221]	new[215]|new[219]|new[221]	_	_
29-31	4627-4629	in	abstract[215]|abstract[219]|abstract[221]	new[215]|new[219]|new[221]	_	_
29-32	4630-4637	general	abstract[215]|abstract[219]|abstract[221]|person	new[215]|new[219]|new[221]|new	_	_
29-33	4638-4639	.	_	_	_	_

#Text=The absorbent polymer consists of cross-linked polyacrylic acid , which was partially neutralized .
30-1	4640-4643	The	person[223]	giv[223]	coref	31-7[0_223]
30-2	4644-4653	absorbent	person[223]	giv[223]	_	_
30-3	4654-4661	polymer	person[223]	giv[223]	_	_
30-4	4662-4670	consists	_	_	_	_
30-5	4671-4673	of	_	_	_	_
30-6	4674-4686	cross-linked	substance[224]	new[224]	coref	31-22[0_224]
30-7	4687-4698	polyacrylic	substance[224]	new[224]	_	_
30-8	4699-4703	acid	substance[224]	new[224]	_	_
30-9	4704-4705	,	_	_	_	_
30-10	4706-4711	which	_	_	_	_
30-11	4712-4715	was	_	_	_	_
30-12	4716-4725	partially	_	_	_	_
30-13	4726-4737	neutralized	_	_	_	_
30-14	4738-4739	.	_	_	_	_

#Text=Proteins can be embedded in this polymer matrix and can be bound , for example , by ionic interactions of its acid moieties to ionic amino acid residues of the protein ( see
31-1	4740-4748	Proteins	animal	new	_	_
31-2	4749-4752	can	_	_	_	_
31-3	4753-4755	be	_	_	_	_
31-4	4756-4764	embedded	_	_	_	_
31-5	4765-4767	in	_	_	_	_
31-6	4768-4772	this	object[227]	new[227]	ana	31-21[0_227]
31-7	4773-4780	polymer	person|object[227]	giv|new[227]	_	_
31-8	4781-4787	matrix	object[227]	new[227]	_	_
31-9	4788-4791	and	_	_	_	_
31-10	4792-4795	can	_	_	_	_
31-11	4796-4798	be	_	_	_	_
31-12	4799-4804	bound	_	_	_	_
31-13	4805-4806	,	_	_	_	_
31-14	4807-4810	for	_	_	_	_
31-15	4811-4818	example	_	_	_	_
31-16	4819-4820	,	_	_	_	_
31-17	4821-4823	by	_	_	_	_
31-18	4824-4829	ionic	abstract[228]	new[228]	_	_
31-19	4830-4842	interactions	abstract[228]	new[228]	_	_
31-20	4843-4845	of	abstract[228]	new[228]	_	_
31-21	4846-4849	its	abstract[228]|object|substance[231]	new[228]|giv|giv[231]	_	_
31-22	4850-4854	acid	abstract[228]|substance|substance[231]	new[228]|giv|giv[231]	coref	31-27
31-23	4855-4863	moieties	abstract[228]|substance[231]	new[228]|giv[231]	_	_
31-24	4864-4866	to	abstract[228]|substance[231]	new[228]|giv[231]	_	_
31-25	4867-4872	ionic	abstract[228]|substance[231]|substance[234]	new[228]|giv[231]|new[234]	coref	33-9[240_234]
31-26	4873-4878	amino	abstract[228]|substance[231]|object|substance[234]	new[228]|giv[231]|new|new[234]	_	_
31-27	4879-4883	acid	abstract[228]|substance[231]|substance|substance[234]	new[228]|giv[231]|giv|new[234]	_	_
31-28	4884-4892	residues	abstract[228]|substance[231]|substance[234]	new[228]|giv[231]|new[234]	_	_
31-29	4893-4895	of	abstract[228]|substance[231]|substance[234]	new[228]|giv[231]|new[234]	_	_
31-30	4896-4899	the	abstract[228]|substance[231]|substance[234]|substance[235]	new[228]|giv[231]|new[234]|giv[235]	coref	33-10[0_235]
31-31	4900-4907	protein	abstract[228]|substance[231]|substance[234]|substance[235]	new[228]|giv[231]|new[234]|giv[235]	_	_
31-32	4908-4909	(	_	_	_	_
31-33	4910-4913	see	_	_	_	_

#Text=Figure 1
32-1	4914-4920	Figure	object[236]	new[236]	coref	34-1[243_236]
32-2	4921-4922	1	object[236]	new[236]	_	_

#Text=A ) . Also , hydrogen bridges from non-ionic protein residues with superabsorber functionalities (
33-1	4923-4924	A	object[238]	new[238]	_	_
33-2	4925-4926	)	object[238]	new[238]	_	_
33-3	4927-4928	.	object[238]	new[238]	_	_
33-4	4929-4933	Also	object[238]	new[238]	_	_
33-5	4934-4935	,	object[238]	new[238]	_	_
33-6	4936-4944	hydrogen	substance|object[238]	new|new[238]	_	_
33-7	4945-4952	bridges	object[238]	new[238]	_	_
33-8	4953-4957	from	object[238]	new[238]	_	_
33-9	4958-4967	non-ionic	object[238]|substance[240]	new[238]|giv[240]	coref	35-8[248_240]
33-10	4968-4975	protein	object[238]|substance|substance[240]	new[238]|giv|giv[240]	_	_
33-11	4976-4984	residues	object[238]|substance[240]	new[238]|giv[240]	_	_
33-12	4985-4989	with	object[238]|substance[240]	new[238]|giv[240]	_	_
33-13	4990-5003	superabsorber	object[238]|substance[240]|object|abstract[242]	new[238]|giv[240]|giv|new[242]	_	_
33-14	5004-5019	functionalities	object[238]|substance[240]|abstract[242]	new[238]|giv[240]|new[242]	_	_
33-15	5020-5021	(	_	_	_	_

#Text=Figure 1
34-1	5022-5028	Figure	object[243]	giv[243]	coref	36-1[249_243]
34-2	5029-5030	1	object[243]	giv[243]	_	_

#Text=B ) or entrapment of enzyme in superabsorber-bound water residues (
35-1	5031-5032	B	person	new	_	_
35-2	5033-5034	)	_	_	_	_
35-3	5035-5037	or	_	_	_	_
35-4	5038-5048	entrapment	abstract[245]	new[245]	_	_
35-5	5049-5051	of	abstract[245]	new[245]	_	_
35-6	5052-5058	enzyme	abstract[245]|substance[246]	new[245]|giv[246]	_	_
35-7	5059-5061	in	abstract[245]|substance[246]	new[245]|giv[246]	_	_
35-8	5062-5081	superabsorber-bound	abstract[245]|substance[246]|substance[248]	new[245]|giv[246]|giv[248]	_	_
35-9	5082-5087	water	abstract[245]|substance[246]|substance|substance[248]	new[245]|giv[246]|new|giv[248]	_	_
35-10	5088-5096	residues	abstract[245]|substance[246]|substance[248]	new[245]|giv[246]|giv[248]	_	_
35-11	5097-5098	(	_	_	_	_

#Text=Figure 1
36-1	5099-5105	Figure	object[249]	giv[249]	_	_
36-2	5106-5107	1	object[249]	giv[249]	_	_

#Text=C ) can be a possible mode of interaction .
37-1	5108-5109	C	abstract	new	coref	37-5[251_0]
37-2	5110-5111	)	_	_	_	_
37-3	5112-5115	can	_	_	_	_
37-4	5116-5118	be	_	_	_	_
37-5	5119-5120	a	abstract[251]	giv[251]	_	_
37-6	5121-5129	possible	abstract[251]	giv[251]	_	_
37-7	5130-5134	mode	abstract[251]	giv[251]	_	_
37-8	5135-5137	of	abstract[251]	giv[251]	_	_
37-9	5138-5149	interaction	abstract[251]|abstract	giv[251]|new	_	_
37-10	5150-5151	.	_	_	_	_

#Text=An ( R )-enantioselective ADH from Lactobacillus brevis ( LB-ADH ) has been shown to be a versatile catalyst for the reduction of a variety of ketones , ranging from aliphatic ketones to benzylic or propargylic ketones .
38-1	5152-5154	An	person[253]	new[253]	_	_
38-2	5155-5156	(	person[253]	new[253]	_	_
38-3	5157-5158	R	person[253]	new[253]	_	_
38-4	5159-5177	)-enantioselective	person[253]	new[253]	_	_
38-5	5178-5181	ADH	abstract[254]	giv[254]	coref	42-8[275_254]
38-6	5182-5186	from	abstract[254]	giv[254]	_	_
38-7	5187-5200	Lactobacillus	abstract[254]	giv[254]	_	_
38-8	5201-5207	brevis	abstract[254]	giv[254]	_	_
38-9	5208-5209	(	_	_	_	_
38-10	5210-5216	LB-ADH	substance	giv	_	_
38-11	5217-5218	)	_	_	_	_
38-12	5219-5222	has	_	_	_	_
38-13	5223-5227	been	_	_	_	_
38-14	5228-5233	shown	_	_	_	_
38-15	5234-5236	to	_	_	_	_
38-16	5237-5239	be	_	_	_	_
38-17	5240-5241	a	object[256]	giv[256]	coref	39-11[263_256]
38-18	5242-5251	versatile	object[256]	giv[256]	_	_
38-19	5252-5260	catalyst	object[256]	giv[256]	_	_
38-20	5261-5264	for	object[256]	giv[256]	_	_
38-21	5265-5268	the	object[256]|abstract[257]	giv[256]|new[257]	_	_
38-22	5269-5278	reduction	object[256]|abstract[257]	giv[256]|new[257]	_	_
38-23	5279-5281	of	object[256]|abstract[257]	giv[256]|new[257]	_	_
38-24	5282-5283	a	object[256]|abstract[257]|abstract[258]	giv[256]|new[257]|new[258]	ana	39-1[0_258]
38-25	5284-5291	variety	object[256]|abstract[257]|abstract[258]	giv[256]|new[257]|new[258]	_	_
38-26	5292-5294	of	object[256]|abstract[257]|abstract[258]	giv[256]|new[257]|new[258]	_	_
38-27	5295-5302	ketones	object[256]|abstract[257]|abstract[258]|substance	giv[256]|new[257]|new[258]|new	coref	38-31[260_0]
38-28	5303-5304	,	_	_	_	_
38-29	5305-5312	ranging	_	_	_	_
38-30	5313-5317	from	_	_	_	_
38-31	5318-5327	aliphatic	substance[260]	giv[260]	_	_
38-32	5328-5335	ketones	substance[260]	giv[260]	_	_
38-33	5336-5338	to	substance[260]	giv[260]	_	_
38-34	5339-5347	benzylic	substance[260]|substance	giv[260]|new	_	_
38-35	5348-5350	or	substance[260]	giv[260]	_	_
38-36	5351-5362	propargylic	substance[260]	giv[260]	_	_
38-37	5363-5370	ketones	substance[260]	giv[260]	_	_
38-38	5371-5372	.	_	_	_	_

#Text=It can be used as an isolated enzyme or as a whole-cell catalyst .
39-1	5373-5375	It	abstract	giv	ana	40-4
39-2	5376-5379	can	_	_	_	_
39-3	5380-5382	be	_	_	_	_
39-4	5383-5387	used	_	_	_	_
39-5	5388-5390	as	_	_	_	_
39-6	5391-5393	an	_	_	_	_
39-7	5394-5402	isolated	_	_	_	_
39-8	5403-5409	enzyme	_	_	_	_
39-9	5410-5412	or	_	_	_	_
39-10	5413-5415	as	_	_	_	_
39-11	5416-5417	a	abstract[263]	giv[263]	_	_
39-12	5418-5428	whole-cell	abstract[263]	giv[263]	_	_
39-13	5429-5437	catalyst	abstract[263]	giv[263]	_	_
39-14	5438-5439	.	_	_	_	_

#Text=In particular , its tolerance towards organic solvents is outstanding .
40-1	5440-5442	In	_	_	_	_
40-2	5443-5453	particular	_	_	_	_
40-3	5454-5455	,	_	_	_	_
40-4	5456-5459	its	abstract|abstract[265]	giv|new[265]	_	_
40-5	5460-5469	tolerance	abstract[265]	new[265]	_	_
40-6	5470-5477	towards	abstract[265]	new[265]	_	_
40-7	5478-5485	organic	abstract[265]|substance[266]	new[265]|giv[266]	_	_
40-8	5486-5494	solvents	abstract[265]|substance[266]	new[265]|giv[266]	_	_
40-9	5495-5497	is	_	_	_	_
40-10	5498-5509	outstanding	_	_	_	_
40-11	5510-5511	.	_	_	_	_

#Text=The stability depends on several factors , such as the nature of the buffer or solvent additives .
41-1	5512-5515	The	abstract[267]	new[267]	_	_
41-2	5516-5525	stability	abstract[267]	new[267]	_	_
41-3	5526-5533	depends	_	_	_	_
41-4	5534-5536	on	_	_	_	_
41-5	5537-5544	several	abstract[268]	new[268]	_	_
41-6	5545-5552	factors	abstract[268]	new[268]	_	_
41-7	5553-5554	,	abstract[268]	new[268]	_	_
41-8	5555-5559	such	abstract[268]	new[268]	_	_
41-9	5560-5562	as	abstract[268]	new[268]	_	_
41-10	5563-5566	the	abstract[268]|abstract[269]	new[268]|new[269]	_	_
41-11	5567-5573	nature	abstract[268]|abstract[269]	new[268]|new[269]	_	_
41-12	5574-5576	of	abstract[268]|abstract[269]	new[268]|new[269]	_	_
41-13	5577-5580	the	abstract[268]|abstract[269]|substance[270]	new[268]|new[269]|new[270]	_	_
41-14	5581-5587	buffer	abstract[268]|abstract[269]|substance[270]	new[268]|new[269]|new[270]	_	_
41-15	5588-5590	or	abstract[268]|abstract[269]	new[268]|new[269]	_	_
41-16	5591-5598	solvent	abstract[268]|abstract[269]|abstract|substance[272]	new[268]|new[269]|new|new[272]	_	_
41-17	5599-5608	additives	abstract[268]|abstract[269]|substance[272]	new[268]|new[269]|new[272]	_	_
41-18	5609-5610	.	_	_	_	_

#Text=In this contribution , the application of a superabsorber-immobilized ADH from L. brevis for an enzymatic reduction of acetophenone ( 1 ) in a flow process is described .
42-1	5611-5613	In	_	_	_	_
42-2	5614-5618	this	abstract[273]	new[273]	_	_
42-3	5619-5631	contribution	abstract[273]	new[273]	_	_
42-4	5632-5633	,	_	_	_	_
42-5	5634-5637	the	abstract[274]	new[274]	_	_
42-6	5638-5649	application	abstract[274]	new[274]	_	_
42-7	5650-5652	of	abstract[274]	new[274]	_	_
42-8	5653-5654	a	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
42-9	5655-5680	superabsorber-immobilized	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
42-10	5681-5684	ADH	abstract[274]|abstract[275]	new[274]|giv[275]	_	_
42-11	5685-5689	from	abstract[274]	new[274]	_	_
42-12	5690-5692	L.	abstract[274]	new[274]	_	_
42-13	5693-5699	brevis	abstract[274]	new[274]	_	_
42-14	5700-5703	for	abstract[274]	new[274]	_	_
42-15	5704-5706	an	abstract[274]|abstract[276]	new[274]|new[276]	_	_
42-16	5707-5716	enzymatic	abstract[274]|abstract[276]	new[274]|new[276]	_	_
42-17	5717-5726	reduction	abstract[274]|abstract[276]	new[274]|new[276]	_	_
42-18	5727-5729	of	abstract[274]|abstract[276]	new[274]|new[276]	_	_
42-19	5730-5742	acetophenone	abstract[274]|abstract[276]|substance[277]	new[274]|new[276]|new[277]	_	_
42-20	5743-5744	(	abstract[274]|abstract[276]|substance[277]	new[274]|new[276]|new[277]	_	_
42-21	5745-5746	1	abstract[274]|abstract[276]|substance[277]	new[274]|new[276]|new[277]	_	_
42-22	5747-5748	)	abstract[274]|abstract[276]|substance[277]	new[274]|new[276]|new[277]	_	_
42-23	5749-5751	in	_	_	_	_
42-24	5752-5753	a	abstract[279]	new[279]	_	_
42-25	5754-5758	flow	abstract|abstract[279]	new|new[279]	_	_
42-26	5759-5766	process	abstract[279]	new[279]	_	_
42-27	5767-5769	is	_	_	_	_
42-28	5770-5779	described	_	_	_	_
42-29	5780-5781	.	_	_	_	_
